Mark Haden
Corporate Officer/Principal bij CLEARMIND MEDICINE INC.
Vermogen: 150 $ op 31-05-2024
Profiel
Mark Haden is currently the Vice President of Business Development at Clearmind Medicine, Inc. He previously worked as the Director of Clinical Trials at Psygen Labs, Inc. from 2021 to 2022 and as the Executive Director at Multidisciplinary Association for Psychedelic Studies Canada from 2017 to 2021.
Haden received his undergraduate and graduate degrees from the University of British Columbia.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
CLEARMIND MEDICINE INC.
0.00% | 31-10-2023 | 133 ( 0.00% ) | 150 $ | 31-05-2024 |
Actieve functies van Mark Haden
| Bedrijven | Functie | Begin |
|---|---|---|
| CLEARMIND MEDICINE INC. | Corporate Officer/Principal | 01-07-2021 |
Eerdere bekende functies van Mark Haden
| Bedrijven | Functie | Einde |
|---|---|---|
Psygen Labs, Inc.
 Psygen Labs, Inc. Pharmaceuticals: GenericHealth Technology Psygen Labs, Inc. is a psychedelics manufacturer that provides non-exclusive access to psychedelic drug products for clinical research and therapeutic applications. The company is based in Calgary, Canada. With over 50 years of combined experience synthesizing psychedelics, the Canadian company is well positioned to be a lead supplier for the emerging commercial market. The CEO of the company is Danny Motyka. | Corporate Officer/Principal | 01-03-2022 |
Opleiding van Mark Haden
| University of British Columbia | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| CLEARMIND MEDICINE INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Psygen Labs, Inc.
Psygen Labs, Inc. Pharmaceuticals: GenericHealth Technology Psygen Labs, Inc. is a psychedelics manufacturer that provides non-exclusive access to psychedelic drug products for clinical research and therapeutic applications. The company is based in Calgary, Canada. With over 50 years of combined experience synthesizing psychedelics, the Canadian company is well positioned to be a lead supplier for the emerging commercial market. The CEO of the company is Danny Motyka. | Health Technology |
